Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subcutaneous ketamine for treatment-resistant depression
RBR-1072m6nvNot yet recruiting
- Sponsor
- Hospital Universitário Onofre Lopes
- Start
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of ketamine in treatment-resistant depression (TRD), sponsored by Hospital Universitário Onofre Lopes. Primary endpoint: Antidepressant response by MADRS. Planned start Jul 2021; status: not yet recruiting.
02
Drugs
ketamine
03
Conditions
treatment-resistant depression (TRD)
Beyond the preview
Go deeper on RBR-1072m6nv.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on RBR-1072m6nv.